氟哌噻吨美利曲辛治疗非小细胞肺癌患者合并抑郁状态的临床研究

目的观察氟哌噻吨美利曲辛治疗非小细胞肺癌（NSCLC）患者合并抑郁状态的临床效果。方法选择NSCLC合并抑郁状态患者76例,随机分为对照组和氟哌噻吨美利曲辛组,各38例,两组均给予NP方案化疗。化疗当日,对照组于早餐后半小时口服维生素C0.2g（2片）;氟哌噻吨美利曲辛组于早餐后半小时口服氟哌噻吨美利曲辛（每片含氟哌噻吨0.5mg,美利曲辛10mg）2片。分别于治疗前及治疗第21、42天应用Zung抑郁自评量表（SDS）、中国癌症患者化学生物治疗生活质量量表（QLQ-CCC）、卡氏功能状态量表（KPS）评定患者抑郁状态及生活质量。结果治疗前两组SDS、QLQ-CCC、KPS评分差异无统计学意义,具有可比性（P〉0.05）。治疗第21、42天,氟哌噻吨美利曲辛组与对照组相比,SDS评分均明显降低（P〈0.01）;治疗第42天,QLQ-CCC各项评分及KPS评分明显升高（P〈0.05）。结论氟哌噻吨美利曲辛可显著改善NSCLC患者的抑郁状态,提高患者的生活质量。

Flupentixol and Melitracen in the Treatment of Non-Small-Cell Lung Cancer(NSCLC) Patients Complicated by Depression

Objective To observe the therapeutic effect of Flupentixol and Melitracen in treating non-small-cell lung cancer（NSCLC） patients accompanied with depression.Methods 76 NSCLC patients with depression were randomly divided into exprimental group （n=38） and control group （n=38）.Both groups received NP chemotherapy,but the control group took 0.2 g of vitamine C （2 tablets） orally 30 min after breakfast every day and the experimental group took 1 mg of Flupentixol and 20 mg of Melitracen every day.The SDS,the QLQ-CCC and KPS rating scales were used 21 and 42 d before and after treatment to assess depression and life quality of the patients.Results There was no significant difference in SDS,QLQ-CCC and KPS rating scales between the 2 groups with comparability before treatment （P0.05）;but SDS scores of the experimental group was significantly lower than that of the control group （P0.01） 21 and 42 d after treatment,and 42 d after treatment,all rating scores of SDS,QLQ-CCC and KPS increased significantly（P0.05）.Conclusion Flupentixol and Melitracen can obviously improve the depressive state and life quality of the patients with NSCLC.